Zobrazeno 1 - 10
of 26
pro vyhledávání: '"R Antón Torres"'
Autor:
M Llinares Esquerdo, A Navarro Ruiz, R Antón Torres, A Andújar Mateos, AM Sánchez García, L Soriano Irigaray
Publikováno v:
Eur J Hosp Pharm
Background Abiraterone acetate (AA) and enzalutamide are authorised oral therapies in the treatment of metastatic castration-resistant prostate cancer (mCRPC), which act by inhibiting androgen synthesis. Purpose To compare the effectiveness of AA and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9951a6d5607a3ed72c842de1357da88a
https://doi.org/10.1136/ejhpharm-2018-eahpconf.219
https://doi.org/10.1136/ejhpharm-2018-eahpconf.219
Autor:
Gabriel Estan-Cerezo, L Soriano-Irigaray, Andrés Navarro-Ruiz, A Andujar-Mateos, FJ Rodríguez-Lucena, R Antón-Torres
Publikováno v:
Clinical pharmacy.
Background The economic impact of human immunodeficiency virus type 1 (HIV-1) infection is increasing in relation to incidence and improvement in patient survival. Clinical trials are essential to evaluate the efficacy and safety of new treatments an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe72994457b5f3d4f8311b6a9c6bf45c
https://doi.org/10.1136/ejhpharm-2017-000640.158
https://doi.org/10.1136/ejhpharm-2017-000640.158
Autor:
R Antón Torres, M. González Delgado, A Navarro Ruiz, AC Murcia López, J. Borrás Blasco, J.F. Navarro Gracia
Publikováno v:
Farmacia Hospitalaria. 30:99-104
Objective: To assess quality of care by an Outpatient Pharmaceutical Care Unit (OPCU) from patient satisfaction regarding the unit's premises and activities. Method: A transversal study performed at the OPCU using a patient survey. Patient opinions w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75a47ae75034efcf5e7deb3bdea320d3
https://doi.org/10.1016/s1130-6343(06)73954-x
https://doi.org/10.1016/s1130-6343(06)73954-x
Atención farmacéutica a pacientes con artritis reumatoide y psoriásica en tratamiento con etanercept
Publikováno v:
Farmacia Hospitalaria. 29:171-176
Resumen Objetivo Evaluar un protocolo de atencion farmaceutica dirigido a pacientes con artritis reumatoide y/o psoriasica que inician tratamiento con etanercept, con el proposito de detectar posibles problemas relacionados con la medicacion y empren
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c369a49e4b9dad690fa803c29fcaad6c
https://doi.org/10.1016/s1130-6343(05)73659-x
https://doi.org/10.1016/s1130-6343(05)73659-x
CP-214 Adherence to tyrosine kinase inhibitor treatments in chronic myeloid leukaemia: A pilot study
Autor:
A Navarro Ruiz, A Martínez Valero, R Antón Torres, AM Sánchez García, A Andújar-Mateos, FJ Rodríguez-Lucena
Publikováno v:
European Journal of Hospital Pharmacy. 23:A94.2-A95
Background The tyrosine kinase inhibitors (TKI), imatinib, dasatinib and nilotinib, have brought about a paradigm change in the treatment of chronic myeloid leukaemia (CML). Previously, patients had a median survival of 3–5 years, while now it is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::348430a96749fff6c86da6b0a9c5b24b
https://doi.org/10.1136/ejhpharm-2016-000875.214
https://doi.org/10.1136/ejhpharm-2016-000875.214
Autor:
R Antón Torres, E García Iranzo, A Navarro Ruiz, A Martínez Valero, FJ Rodríguez-Lucena, R Gutiérrez Vozmediano
Publikováno v:
European Journal of Hospital Pharmacy. 22:A69.1-A69
Background Patients with multiple antiretroviral therapy (MAT), defined as a combination of at least 3 drugs with different mechanisms of action, are on a difficult and costly treatment which may also affect treatment adherence. Purpose To describe c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::681d6b5d020741f71bfee3ae559fe109
https://doi.org/10.1136/ejhpharm-2015-000639.164
https://doi.org/10.1136/ejhpharm-2015-000639.164
Publikováno v:
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 29(3)
To evaluate a pharmaceutical care protocol for patients with rheumatoid arthritis (RA) or psoriatic arthritis who begin treatment with etanercept with the objective of identifying potential medication-related problems and implementing therapeutic mea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8da293915e4f325adc8867261c8fb37d
https://pubmed.ncbi.nlm.nih.gov/16013943
https://pubmed.ncbi.nlm.nih.gov/16013943
Publikováno v:
Medicina clinica. 113(14)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2d15e49cc47a07070936aa7d790bb711
https://pubmed.ncbi.nlm.nih.gov/10786340
https://pubmed.ncbi.nlm.nih.gov/10786340
Autor:
A Garcia-Monsalve, I Triano-García, R Antón-Torres, JM delMoral-Sánchez, C Matoses-Chirivella, FJ Rodríguez-Lucena, L Soriano-Irigaray, Jiménez-Pulido Ip, Ana Cristina Murcia-López, Andrés Navarro-Ruiz
Publikováno v:
European Journal of Hospital Pharmacy. 20:A41.2-A41
Background Medicines reconciliation is done to avoid errors in patient treatment such as omissions, duplications, dosing errors, drugs not included in the hospital formulary or drug interactions. Admission to hospital is one of the best times to reco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20947e33cb445d94881d234843bcf504
https://doi.org/10.1136/ejhpharm-2013-000276.114
https://doi.org/10.1136/ejhpharm-2013-000276.114
Autor:
R Gutiérrez Vozmediano, C Matoses Chirivella, A Navarro Ruiz, A Martínez Valero, Laura Frías Soriano, FJ Rodríguez-Lucena, I Triano Garcia, PJ Moya-Forcén, R Antón Torres, AC Murcia López
Publikováno v:
European Journal of Hospital Pharmacy. 20:A38.1-A38
Background The average hospitalised patient is subject to at least one medicines error per day. More than 40% of medicines errors are believed to result from inadequate medicines reconciliation. Purpose To investigate the introduction of a medicines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::846da1c8d6def4d9bc879112629c8642
https://doi.org/10.1136/ejhpharm-2013-000276.105
https://doi.org/10.1136/ejhpharm-2013-000276.105